Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constance A Benson

Showing results (51-60 of 104) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Endocrinology and Metabolism|November 9, 2006
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trialKathleen Mulligan, Robert Zackin, Jamie H Von Roenn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
AIDS (London, England)|November 30, 2020
Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapyKristine M Erlandson, Kunling Wu, Jordan E Lake, et al.
AIDS (London, England)|June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsTimothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Open Forum Infectious Diseases|March 22, 2019
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized TrialJonathan Z Li, Paul E Sax, Vincent C Marconi, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteersKelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2013
TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigensRamachandran Vignesh, Nagalingeswaran Kumarasamy, Andrew Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Survival differences and artemisinin resistance in severe malaria among HIV coinfected patients: data from MozambiqueIrina Mendes de Sousa, Erin McArthur, Lúcia Chambal, et al.
Pageof 11

Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Endocrinology and Metabolism|November 9, 2006
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trialKathleen Mulligan, Robert Zackin, Jamie H Von Roenn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
AIDS (London, England)|November 30, 2020
Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapyKristine M Erlandson, Kunling Wu, Jordan E Lake, et al.
AIDS (London, England)|June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsTimothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Open Forum Infectious Diseases|March 22, 2019
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized TrialJonathan Z Li, Paul E Sax, Vincent C Marconi, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteersKelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2013
TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigensRamachandran Vignesh, Nagalingeswaran Kumarasamy, Andrew Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Survival differences and artemisinin resistance in severe malaria among HIV coinfected patients: data from MozambiqueIrina Mendes de Sousa, Erin McArthur, Lúcia Chambal, et al.
Pageof 11